Compound ID | 2884
CMTX101
Class: Antibody
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Broad-spectrum activity; developed for community acquired bacterial pneumoniae (Pseudomonas aeruginosa) |
| Description: | Immune-enabling antibody therapy; intended for infections associated with biofilm |
| Institute where first reported: | Clarametyx Biosciences, Inc. |
| Year first mentioned: | 2023 |
| Highest developmental phase: | Phase 1 (NCT06159725) |
| Development status: | Active as of 2024 |
| External links: | |
| Guide to Pharmacology: | CMTX-101 |
| Main Source: | https://classic.clinicaltrials.gov/ct2/show/NCT06159725 |
| Citation: | https://www.mdpi.com/2079-6382/11/1/104 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us.
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.